ClinicalTrials.gg
RecruitingNCT07944261MILD-EFFECTUpdated Nov 18, 2026

Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits

A Phase 3 interventional study of Tenecteplase 0.18 mg/kg and Tenecteplase 0.25 mg/kg in Acute Ischemic Stroke and Minor Ischemic Stroke, sponsored by Shandong Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shandong Provincial Hospital · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,324
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.

Planned enrollment
11th of 59
1,324 · median 466
Started
2026
with 10 others
Phase 3
37 of 59
23 open now
Primary completion
2029-04
later than 25 of 31 live
Registered
58th of 59
by date

Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 11th largest by planned enrollment, is one of 11 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 25 of the 31 other live ones, and was the 58th registered.

Ischemic Stroke

2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing tenecteplase in Ischemic Stroke, or all of them as a file.
02

Study summary

This study will compare two doses of a clot-dissolving medicine called tenecteplase (TNK), specifically recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA), in adults with a mild ischemic stroke that causes disabling symptoms. An ischemic stroke occurs when a blood clot blocks blood flow to the brain. Even a mild stroke can cause problems that prevent a person from carrying out basic daily activities or returning to work.

The main question is whether a lower dose of rhTNK-tPA helps patients recover nearly as well as the standard dose, within a predefined acceptable difference. The study will also compare bleeding and other side effects between the two doses.

Up to 1,324 participants at multiple hospitals will be randomly assigned to receive either the lower dose (0.18 mg/kg, up to 16 mg) or the standard dose (0.25 mg/kg, up to 25 mg). Each participant will receive one injection into a vein within 4.5 hours of stroke onset, along with usual stroke care. Participants and treating doctors will know which dose is given, but the assessors evaluating recovery will not.

Participants will be followed for approximately 90 days. Researchers will assess recovery, ability to carry out daily activities, quality of life, bleeding, and other medical problems. The main outcome is the proportion of participants who have no symptoms or no significant disability at about 90 days after treatment.

03

Conditions studied

  • Acute Ischemic Stroke
  • Minor Ischemic Stroke

Browse trials for

Keywords

  • Minor Ischemic Stroke
  • Disabling Neurological Deficits
  • Tenecteplase
  • Recombinant Human TNK Tissue-Type Plasminogen Activator
  • Intravenous Thrombolysis
  • Low-Dose Tenecteplase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Clinical diagnosis of acute ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) score ≤5.
  3. Presence of clearly disabling neurological deficits that persist and prevent the participant from independently performing at least one basic activity of daily living (including bathing, dressing, walking, toileting, personal hygiene, and eating) and/or returning to their previous work.
  4. Time from stroke onset to treatment \<4.5 hours, with onset defined as the time of symptom onset or the last known well time.
  5. Pre-stroke modified Rankin Scale (mRS) score ≤1.
  6. Voluntary participation and written provided by the participant or their legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Intracranial hemorrhage, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma.
  2. NIHSS item 1a score >2.
  3. Planned endovascular treatment before randomization.
  4. History of intracranial hemorrhage, or presence of an intra-axial intracranial tumor, giant intracranial aneurysm, or arteriovenous malformation.
  5. History of stroke within the preceding 3 months.
  6. Recent anticoagulant treatment with coagulation parameters that do not meet the safety requirements for thrombolysis.
  7. Active internal bleeding or an acute bleeding tendency, including a count \<100 × 10⁹/L.
  8. Concomitant bacterial endocarditis, pericarditis, acute pancreatitis, or other severe, difficult-to-control infections.
  9. History of major trauma (e.g., severe head injury within the preceding 3 months), surgery or invasive procedures (e.g., intracranial or spinal canal surgery within the preceding 3 months, major surgery within the preceding 2 weeks, or arterial puncture at a site not amenable to compression within the preceding week), or bleeding (e.g., gastrointestinal or urinary tract bleeding within the preceding 3 weeks).
  10. Persistent uncontrolled hypertension despite active antihypertensive treatment: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg.
  11. Blood glucose \<2.8 mmol/L or >22.22 mmol/L. Eligibility may be reassessed after correction of blood glucose if clearly disabling neurological deficits associated with minor stroke persist and the participant meets the diagnostic criteria for acute ischemic stroke and the eligibility requirements for intravenous thrombolysis.
  12. Postictal paresis (Todd's paresis), or other neurological or psychiatric conditions resulting in inability or unwillingness to cooperate.
  13. Known allergy to the active ingredient rhTNK-tPA or any of its .
  14. Current participation in another interventional medical device or drug study, or completion of participation in such a study less than 30 days previously.
  15. Pregnancy, breastfeeding, or unwillingness of a female participant to use effective during the trial.
  16. Other serious diseases associated with a of less than 6 months.
  17. Any other condition that, in the investigator's judgment, may substantially increase bleeding risk, interfere with study assessments, or render the participant unsuitable for the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,324 participants (estimated)

Study arms

  • Experimental
    Low-Dose Tenecteplase (rhTNK-tPA)

    Participants will receive rhTNK-tPA at 0.18 mg/kg, with a maximum dose of 16 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

    Drug: Tenecteplase 0.18 mg/kg

  • Active comparator
    Standard-Dose Tenecteplase (rhTNK-tPA)

    Participants will receive rhTNK-tPA at 0.25 mg/kg, with a maximum dose of 25 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

    Drug: Tenecteplase 0.25 mg/kg

Interventions

  • DrugTenecteplase 0.18 mg/kg

    Drug page: Tenecteplase

    Tenecteplase (rhTNK-tPA) will be administered at 0.18 mg/kg, with a maximum dose of 16 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

    Also known as: rhTNK-tPA, Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection

  • DrugTenecteplase 0.25 mg/kg

    Drug page: Tenecteplase

    Tenecteplase (rhTNK-tPA) will be administered at 0.25 mg/kg, with a maximum dose of 25 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

    Also known as: rhTNK-tPA, Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-1

    The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-1 indicates no significant disability.

    Time frame: 90 ± 7 days after randomization

Secondary outcomes

  1. Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-2

    The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-2 indicates functional independence.

    Time frame: 90 ± 7 days after randomization

  2. Distribution of Modified Rankin Scale (mRS) Scores

    The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. The distribution across all seven categories (0-6) will be assessed.

    Time frame: 90 ± 7 days after randomization

  3. Proportion of Participants With a National Institutes of Health Stroke Scale (NIHSS) Score of 0-1

    The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. An NIHSS score of 0-1 indicates no or minimal neurological deficits.

    Time frame: 22-36 hours after randomization and at day 7 ± 1 or discharge, whichever occurs first

  4. Proportion of Participants With an Increase From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score

    The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological worsening is defined as an increase of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline.

    Time frame: Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first

  5. Proportion of Participants With a Decrease From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score

    The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological improvement is defined as a decrease of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline.

    Time frame: Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first

  6. Proportion of Participants With a COSMOS score Grade of 0-1

    The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence or worse), with higher scores indicating worse outcomes. The proportion of participants with a COSMOS grade of 0-1 will be assessed.

    Time frame: 90 ± 7 days after randomization

  7. COSMOS Score

    The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence for an instrumental or basic activity of daily living or worse), with higher scores indicating worse outcomes. The distribution of COSMOS grades from 0 to 6 at 90 days will be assessed.

    Time frame: 90 ± 7 days after randomization

  8. Health-Related Quality of Life Assessed by EQ-5D-3L and EQ VAS

    The EuroQol Five-Dimension Three-Level Questionnaire (EQ-5D-3L) assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three response levels, ranging from 1 (no problems) to 3 (extreme problems or inability to perform the activity), with higher levels indicating worse health status. The accompanying EuroQol Visual Analogue Scale (EQ VAS) assesses self-rated overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better health status.

    Time frame: 90 ± 7 days after randomization

  9. Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 36 Hours

    Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death.

    Time frame: Within 36 hours after study drug administration

  10. Incidence of Any Intracranial Hemorrhage Within 36 Hours

    Any intracranial hemorrhage is defined as the presence of intracranial bleeding detected by brain computed tomography (CT) or magnetic resonance imaging (MRI), regardless of whether neurological deterioration or clinical symptoms are present. Both symptomatic and asymptomatic intracranial hemorrhages are included.

    Time frame: Within 36 hours after study drug administration

  11. Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 7 Days

    Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death. Events occurring within 7 days after study drug administration will be assessed.

    Time frame: Within 7 days after study drug administration

  12. Incidence of Major Extracranial Bleeding According to ISTH Criteria

    Major extracranial bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria as bleeding outside the cranium meeting at least one of the following: fatal bleeding; symptomatic bleeding in a critical extracranial area or organ, including intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome; a decrease in hemoglobin of ≥2 g/dL; or transfusion of ≥2 units of whole blood or red blood cells.

    Time frame: Within 7 days after study drug administration

  13. Proportion of Participants With a Modified Rankin Scale (mRS) Score of 5-6

    The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 5-6 indicates severe disability or death.

    Time frame: 90 ± 7 days after randomization

  14. All-Cause Mortality

    Time frame: Within 90 days after randomization

  15. Proportion of Participants Experiencing at Least One Adverse Event

    Time frame: Within 90 days after study drug administration

  16. Proportion of Participants Experiencing at Least One Serious Adverse Event

    Time frame: Within 90 days after study drug administration

07

Study locations

1 of 1 sites recruiting
  • Shandong Provincial Hospital Affiliated to Shandong First Medical University
    Jinan, Shandong 250021, China
    Recruiting
    • Qinjian Sun, MD · Contactsqj1210@163.com · +86-0531-68773275
    • QinJian Sun · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2029, 30 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 30 months is close to that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 18, 2026
StartActual
Oct 15, 2026
Primary completionEst.
Apr 2029
CompletionEst.
Jul 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07944261
Lead sponsor
Shandong Provincial Hospital
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Oct 15, 2026
Primary completion
Apr 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

QinJian Sun
Contact
sqj1210@163.com
86-0531-68773275
QinJian Sun
principal investigator · Shandong Provincial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion